NovaBridge Biosciences
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBP research report →
About the company
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor.
- CEO
- Xi-Yong Fu
- IPO
- 2020
- Employees
- 32
- HQ
- Rockville, MD, US
Price Chart
- Market Cap
- $246.67M
- P/E
- -24.64
- P/S
- 0.00
- P/B
- 22.01
- EV/EBITDA
- -52.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.59%
- ROIC
- -94.82%
- Revenue
- $0 · 0.00%
- Net Income
- $-6,614,616 · 95.92%
- EPS
- $-0.16 · 96.46%
- Op Income
- $-13,476,696
- FCF YoY
- 94.65%
- 52W High
- $6.79
- 52W Low
- $1.46
- 50D MA
- $1.91
- 200D MA
- $3.29
- Beta
- 1.48
- Avg Volume
- 879.47K
Get TickerSpark's AI analysis on NBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Fu Wei | other | 1,087,720 |
| Jun 29, 26 | Fu Wei | other | 1,010,100 |
| Jun 29, 26 | Fu Wei | other | 725,140 |
| Jun 22, 26 | Cao Sean Wuxiong | other | 181,290 |
| Jun 22, 26 | Cao Sean Wuxiong | other | 181,280 |
| Jun 17, 26 | Dennis Phillip Andrew | other | 23,695 |
| Jun 18, 26 | Dennis Phillip Andrew | sell | 8,494 |
| Jun 17, 26 | Dennis Phillip Andrew | other | 10,302 |
| May 30, 26 | Xu Cong Claire | other | 9,382 |
| Jun 1, 26 | Xu Cong Claire | sell | 3,494 |
Our NBP coverage
Recent articles, reports, and earnings notes.
No research on NBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBP report →Similar companies
Peers in the same neighborhood.